[Statins in chronic renal disease].
Hypertriglyceridemia and low HDL-c are common features in patients with chronic renal failure. Cardiovascular mortality is substantially increased in the presence of chronic renal disease (10-20 times higher). There is evidence from clinical trials with statins suggesting their protective role in the progression of renal disease. In addition, reduced rates of non-fatal myocardial infarction and cardiac mortality were seen after renal transplant in patients receiving fluvastatin. However, a recent study with atorvastatin failed to demonstrate reduction in cardiovascular morbidity and mortality among diabetic patients on hemodialysis therapy. Ongoing trials will define the precise role of statins in this subset of patients.
Ferreira
Soraia R C
SR
Faculdade de Medicina, PUC de Campinas.
Rocha
Aloísio M
AM
Saraiva
José Francisco K
JF
D001938:Brazil / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D016031:Liver Transplantation / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors